PRTO News and Press, Proteon Therapeutics Inc.

Shares of ArTara to commence trading on Nasdaq under new ticker symbol “TARA” effective January 10, 2020 Company completes previously announced equity financing of $42.5 million concurrently with the closing of the merger Combined company will focus on developing tre...

NEW YORK , Dec. 3, 2019 /PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street in downtown New York City , is investigating potential claims involving the directors and officers regarding possible breaches of fiduciary duties and other violations of law related t...

NEW YORK , Nov. 22, 2019 /PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street in downtown New York City , is investigating potential claims involving the directors and officers regarding possible breaches of fiduciary duties and other violations of law rel...

Proteon Therapeutics (NASDAQ: PRTO ): Q3 GAAP EPS of -$0.08 beats by $0.01 . More news on: Proteon Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

WALTHAM, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (“Proteon” or the “Company”) (Nasdaq: PRTO), a company that has historically focused on the development of novel, first-in-class pharmaceuticals to address the medical needs of patie...

NEW YORK , Sept. 25, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Proteon Therapeutics, Inc. (NASDAQ: PRTO) on behalf of Proteon shareholders concerning the proposed merger with ArTara Therapeutics, Inc. ...

NEW YORK, Sept. 24, 2019 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, is investigating the following companies: Proteon Therapeutics, Inc. (NASDAQ: PRTO ) The investigation concerns whether Proteon and its board of directors violated the federal securitie...

Proteon Therapeutics (NASDAQ: PRTO ) and privately held ArTara Therapeutics have agreed to a tie-up in a reverse merger transaction after which the combined company will do business under the ArTara name. Shares will trade under the ticker "TARA." More news on: Proteon Therapeutics, Inc....

Transaction to Create NASDAQ-Listed Rare and Specialty Disease Therapeutic Company Focused on Immunology and Metabolic Disorders $42.5M Concurrent Financing to be Led by a Syndicate of Healthcare Dedicated Investors Companies to Hold Conference Call on September 24 th at 8:30AM ED...

Proteon Therapeutics (NASDAQ: PRTO ): Q2 GAAP EPS of -$0.27 misses by $0.14 . More news on: Proteon Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...